Screening forUGT1A1Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia

Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1

(2014) Jeffrey L. Lennox et al.   ANNALS OF INTERNAL MEDICINE

Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202

(2014) Daniel H. Johnson et al.   Pharmacogenetics and Genomics

Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

(2013) Eric S. Daar   ANNALS OF INTERNAL MEDICINE

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results

(2013) Joel E. Gallant et al.   JOURNAL OF INFECTIOUS DISEASES

Clinical Significance of Hyperbilirubinemia Among HIV-1–Infected Patients Treated with Atazanavir/Ritonavir Through 96 Weeks in the CASTLE Study

(2012) Cheryl McDonald et al.   AIDS PATIENT CARE AND STDS

Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease

(2012) Bruce R Schackman et al.   ANTIVIRAL THERAPY

Impact of UGT1A1 Gilbert Variant on Discontinuation of Ritonavir-Boosted Atazanavir in AIDS Clinical Trials Group Study A5202

(2012) Heather J. Ribaudo, Eric S. Daar, Camlin Tierney, Gene D. Morse, Katie Mollan, Paul E. Sax, Margaret A. Fischl, Ann C. Collier, David W. Haas et al.   JOURNAL OF INFECTIOUS DISEASES

Bilirubin—A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy

(2011) Dinko Rekić et al.   AAPS Journal

Short Communication: Use of Serum Bilirubin Levels as Surrogate Marker of Early Virological Response to Atazanavir-Based Antiretroviral Therapy

(2011) Judit Morello et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatment–Naive, HIV‐Infected Subjects: Week 48 Data from the Altair Study

(2010) Rebekah L. Puls et al.   CLINICAL INFECTIOUS DISEASES

Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study

(2010) Rubin Lubomirov et al.   JOURNAL OF INFECTIOUS DISEASES

Hyperbilirubinemia during Atazanavir Treatment in 2,404 Patients in the Italian Atazanavir Expanded Access Program and MASTER Cohorts

(2009) C. Torti et al.   INFECTION

Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients

(2009) D. R (Niel) Malan et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

(2008) Jean-Michel Molina et al.   LANCET